Search
for
Sort by
Research 541–570 of 879
- Topical latanoprost acid for female androgenetic alopecia: a pilot proof-of-concept trial with mechanistic evidence of prostaglandin F2α receptor activation
- DERMATOLOGICAL AND SYSTEMIC REACTIONS TO HAIR DYES: CURRENT EVIDENCE AND MANAGEMENT
- Lipid nanocarriers as innovative strategies for hair regrowth
- The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
- Case Report: Secondary syphilitic alopecia following non-penetrative sexual contact: a case of initial misdiagnosis
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
- Managing androgenic alopecia with individualised homeopathic medicine and biochemic remedies- An evidence based single case report
- Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
- Case Report: Compound heterozygous variants in LSS and TSPEAR genes causing hypotrichosis type 14 complicated with ectodermal dysplasia type 14
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Familial Pure Hair–Nail Ectodermal Dysplasia in Yemen: A Father–Son Case Report with Clinical Correlation
- Hair for the Long Haul: Alopecia Areata Cases and Considerations
- Alopesi Tedavisinde Kullanılan İlaç Tedavileri ve Yeni Yaklaşımlar
- Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
- Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
- Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- Baricitinib in the Management of Severe Alopecia Areata: A Report of Two Cases With Sustained Clinical Response
- Role of microneedling in treatment of alopecia areata
- Scalp hair cortisol concentration in patients with alopecia areata and correlate its level with the disease variables
- Patient Validation of Estimation of Health Utility Values in Alopecia Areata
- Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
- Medical Physics in Aesthetic Medicine: Innovations and Techniques for Cosmetic Procedures in 2025
- The evaluation of IL-4 VNTR intron 3 and TNF-α (rs1799964) gene polymorphisms in Egyptian patients with alopecia areata: a case–control study
- Hair Product Allergy: A Review of Epidemiology and Management
- Survey on Alopecia Areata Patients’ Reported Factors that Determine Severity of Alopecia Areata: A Nationwide Multicenter Study